Business Context and Reporting Period
This Form 8-K was filed by BiomX Inc. on July 10, 2026. The report addresses compliance issues with NYSE American listing standards regarding the issuance of common stock in connection with the acquisition of a 60% interest in Dr. Frucht Systems Ltd. and a related line of credit.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins. The only specific financial figures disclosed relate to a capital transaction:
- Convertible Note Principal: $379,000
- Shares Issued (Subsequently Cancelled): 1,013,637 restricted shares of common stock
- Revolving Line of Credit: Up to $2,000,000
Material Changes
The primary material change reported is the cancellation of 1,013,637 shares of common stock (the "Conversion Shares") issued on June 2, 2026. These shares were issued to assignees of Mandragola Ltd. upon the partial conversion of a $379,000 convertible promissory note. The cancellation was executed on July 10, 2026, to regain compliance with Section 712 of the NYSE American Company Guide, which requires stockholder approval for issuances exceeding 20% of outstanding shares in connection with acquisitions.
Outlook, Risks, and Management Commentary
Management intends to seek stockholder approval for the issuances related to the acquisition and line of credit at a future meeting. However, the filing explicitly states there can be no assurance that such approval will be obtained. Key risks include:
- Failure to obtain required stockholder approval on the anticipated timeline or at all.
- Potential further action by the NYSE American Exchange regarding the listing of the Company's common stock.
- Uncertainty regarding the ability to maintain compliance with continued listing standards.
Investor Verification Checklist
- Verify the status of the pending stockholder meeting to approve the Related Transactions.
- Confirm whether the NYSE American has issued any further notices regarding the Company's listing status.
- Review the terms of the $2,000,000 revolving line of credit with Mandragola Ltd. to understand repayment obligations if stockholder approval is not granted.
- Monitor future filings for updates on the acquisition of Dr. Frucht Systems Ltd. and the re-issuance of shares if approved.